Skip to content
DataLookout
Menu

NCT07897669

A Real-world Study to Learn About of the Characteristics and Outcomes of Advanced or Metastatic Bladder Cancer Patients With Different Histologies

StatusActive, Not Recruiting
PhaseNot specified
SponsorPfizer
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Minor Trial status changed: Not Yet Recruiting → Active, Not Recruiting
    • Start date changed from estimate of Oct 21, 2026 to Nov 4, 2026
    • Study sites: 0 to 1
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Distribution of First-Line Treatment Regimens by Predominant Histology
Timeframe: Up to 2 Years

Secondary (2)

Real world Progression Free Survival (rwPFS)
Real world Overall Tumor Response (rwOTR)

Arms and interventions

la/mBC

Patients with Locally Advanced or Metastatic Bladder Carcinoma (la/mBC) who received first line treatment.

Sites

1 site in 1 country

  • Pfizer New YorkNew York, New York, United States